Prospective use of RT-PCR for PML/RARa might be used to guide a total tehrapy approach in APL, including refined diagnosis, front-line treatment, assessment of response and anticipated salvage therapy for patients who undergo molecular relapse.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
600
Unità Operativa Ematologia 1 - Università degli Studi di Bari
Bari, Italy
RECRUITINGDiv. di Ematologia IRCCS Policlinico S. Matteo
Pavia, Italy
RECRUITINGA.O Umberto I
Roma, Italy
RECRUITINGTreatment-related toxicity event rate during the ATRA-including consolidation treatment
Time frame: At the end of the study
Event Free Survival, Molecular and Hematological Disease-Free and Overall Survival in each risk group
Time frame: At the end of the study
The rates of molecular remission, after consolidation, in each risk group
Time frame: At the end of the study
Induction morbidity and mortality after the inclusion of the prophylactic measures for the ATRA Syndrome and hemorrhagic complications
Time frame: At the end of the study
The overall toxicity of induction, consolidation, and maintenance chemotherapy in each risk group
Time frame: At the end of the study
The impact on survival of a "total" treatment approach for APL including molecular evaluation of minimal residual disease and salvage tehrapy administration at the time of molecular or hematological relapse
Time frame: At the end of the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.